Efinopegdutide is under clinical development by Hanmi Pharmaceuticals and currently in the Phase II in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect Efinopegdutide’s likelihood of approval (LoA) and phase transition for Non Alcoholic Fatty Liver Disease (NAFLD) took place on 03 Nov 2022, which increased the likelihood that the drug progresses to the next phase in its clinical pathway and increased the likelihood of final approval for this indication.

In addition, the same event on 03 Nov 2022 increased Efinopegdutide’s Phase Transition Success Rate (PTSR) for Non-Alcoholic Steatohepatitis (NASH).

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their Efinopegdutide Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

Efinopegdutide overview

Efinopegdutide is under development for the treatment of nonalcoholic steatohepatitis, obesity, nonalcoholic fatty liver disease (NAFLD), and type 2 diabetes. The therapeutic candidate is administered subcutaneously. The drug candidate is a long acting glucagon like peptide (GLP) acting as dual agonist of GLP-1 receptor and glucagon receptor. It is based on lapscovery technology. The drug candidate is a new molecular entity (NME).

Hanmi Pharmaceuticals overview

Hanmi Pharmaceuticals, a subsidiary of Hanmi Science Co Ltd, develops prescription drugs and over the counter (OTC) drugs. The company’s prescription drugs include antibiotics, antidiarrheal, osteoporosis, liver supplements and antiemetics. It provides OTC products such as nutritional supplements, calcium supplement, vitamins, among others. Hanmi Pharmaceuticals products are used in the treatment of cancer, depression, dementia, dermatology, diabetes, anti-inflammatory, cardiovascular, epilepsy, hepatitis, hypnotics, osteoarthritis, gastrointestinal, osteoporosis and others. The company operates through its manufacturing facilities located in Hwaseong, Songpa and Pyeongtaek, South Korea. Hanmi Pharmaceuticals is headquartered in Seoul, South Korea.

Quick View Efinopegdutide LOA Data

Report Segments
  • Innovator
Drug Name
  • Efinopegdutide
Administration Pathway
  • Subcutaneous
Therapeutic Areas
  • Gastrointestinal
  • Metabolic Disorders
Key Developers
Highest Development Stage
  • Phase II

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.